Compass Therapeutics, Inc. (CMPX)

Currency in USD
2.780
-0.130(-4.47%)
Closed·
Pre Market
2.799+0.019(+0.68%)
·
CMPX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
CMPX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.7402.920
52 wk Range
1.0704.080
Key Statistics
Prev. Close
2.78
Open
2.92
Day's Range
2.74-2.92
52 wk Range
1.07-4.08
Volume
375.02K
Average Volume (3m)
825.16K
1-Year Change
208.33%
Book Value / Share
0.8
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CMPX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
12.800
Upside
+360.43%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Compass Therapeutics, Inc. News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Compass Therapeutics, Inc. Company Profile

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company’s lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; and CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies. It also develops CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A; and VEGF-IO Bispecific / Multiple, a bispecific antibody engages the angiogenesis pathway and anti-tumor immune that targets, including immune checkpoints, as well as analyzes VEGF combinations with other immune response-related proteins. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.

Compare CMPX to Peers and Sector

Metrics to compare
CMPX
Peers
Sector
Relationship
P/E Ratio
−7.0x−1.8x−0.5x
PEG Ratio
0.49−0.240.00
Price/Book
3.5x2.4x2.6x
Price / LTM Sales
452.3x51.7x3.3x
Upside (Analyst Target)
236.9%313.8%43.4%
Fair Value Upside
Unlock3.3%7.1%Unlock

Analyst Ratings

10 Buy
0 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 12.800
(+360.43% Upside)

Earnings

Latest Release
May 08, 2025
EPS / Forecast
-0.12 / -0.11
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

CMPX Income Statement

People Also Watch

44.680
SMR
-2.72%
10.860
COGT
-1.00%
3.510
IMRX
-0.28%
178.95
IQV
+0.82%
50.45
AKRO
-4.43%

FAQ

What Stock Exchange Does Compass Therapeutics, Trade On?

Compass Therapeutics, is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Compass Therapeutics,?

The stock symbol for Compass Therapeutics, is "CMPX."

What Is the Compass Therapeutics, Market Cap?

As of today, Compass Therapeutics, market cap is 384.43M.

What Is Compass Therapeutics,'s Earnings Per Share (TTM)?

The Compass Therapeutics, EPS (TTM) is -0.40.

When Is the Next Compass Therapeutics, Earnings Date?

Compass Therapeutics, will release its next earnings report on 05 Nov 2025.

From a Technical Analysis Perspective, Is CMPX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Compass Therapeutics, Stock Split?

Compass Therapeutics, has split 0 times.

How Many Employees Does Compass Therapeutics, Have?

Compass Therapeutics, has 35 employees.

What is the current trading status of Compass Therapeutics, (CMPX)?

As of 08 Aug 2025, Compass Therapeutics, (CMPX) is trading at a price of 2.78, with a previous close of 2.78. The stock has fluctuated within a day range of 2.74 to 2.92, while its 52-week range spans from 1.07 to 4.08.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.